|
Sign In to gain access to subscriptions and/or personal tools.
|
Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon ß-1a
Richard A Rudick
Department of Neurology (Mellen Center), The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Elizabeth Fisher
Department of Biomedical Engineering, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Jar-Chi Lee
Department of Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Jeffrey T Duda
Department of Biomedical Engineering, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Jack Simon
Department of Radiology-MRI, University of Colorado Health Sciences Center, Denver, Colorado, USA
Brain atrophy is a relevant surrogate marker of the disease process in multiple sclerosis (MS) because it represents the net effect of various pathological processes leading to brain tissue loss. There are various approaches to quantifying central nervous system atrophy in MS. We have focused on a normalized measure of whole brain atrophy, the brain parenchymal fraction (BPF). BPF is defined as the brain parenchymal volume, divided by the volume within the surface of the brain. We applied this method to an MRI data set generated during a phase III clinical trial of interferon ß-1a (AVONEX). The purpose of the current study is to further explore clinical and MRI correlates of the BPF, particularly as they relate to relapse rate and Kurtzke's Expanded Disability Status Score (EDSS); and to further explore the therapeutic effects observed in interferon ß-1a recipients. Of all demographic and disease measures in the clinical trial data base, T2 lesion volume most closely correlated with BPF in cross sectional studies, and was the baseline factor most closely correlated with progressive brain atrophy in the subsequent 2 years. We also observed that change in T2 lesion volume was the disease measure most closely correlated with change in BPF during 2 years of observation. Of interest, relapse number and EDSS change during 2 years were only weakly correlated with BPF change during the same period. Disability progression, defined as sustained worsening of at least 1.0 EDSS points from baseline, persisting at least 6 months, was associated with significantly greater brain atrophy progression. We observed a therapeutic effect of interferon ß-1a in the second year of the clinical trial, and this beneficial effect was not accounted for by change in gadolinium enhanced lesion volume, or by corticosteroid medication within 40 days of the final MRI scan. The BPF is an informative surrogate marker for destructive pathological processes in relaping MS patients, and is useful in demonstrating treatment effects in controlled clinical trials. The significance of progressive brain atrophy during relapsing MS will be assessed by measuring clinical and MRI changes in prospective follow up studies.
Key Words: multiple sclerosis • magnetic resonance imaging • brain atrophy • interferon beta
Multiple Sclerosis, Vol. 6, No. 6,
365-372 (2000)
DOI: 10.1177/135245850000600601
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
Z. Liptak, A.M. Berger, M.P. Sampat, A. Charil, O. Felsovalyi, B.C. Healy, P. Hildenbrand, S.J. Khoury, H.L. Weiner, R. Bakshi, et al.
Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis
AJNR Am. J. Neuroradiol.,
September 1, 2008;
29(8):
1465 - 1470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Minneboo, B Jasperse, F Barkhof, B M J Uitdehaag, D L Knol, V de Groot, C H Polman, and J A Castelijns
Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters
J. Neurol. Neurosurg. Psychiatry,
August 1, 2008;
79(8):
917 - 923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Duan, P.G. Hildenbrand, M.P. Sampat, D.F. Tate, I. Csapo, B. Moraal, R. Bakshi, F. Barkhof, D.S. Meier, and C.R.G. Guttmann
Segmentation of Subtraction Images for the Measurement of Lesion Change in Multiple Sclerosis
AJNR Am. J. Neuroradiol.,
February 1, 2008;
29(2):
340 - 346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Juha, S. Leszek, F. Sten, H. Jan, B. Jakob, F. Olof, and K. W. Maria
Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development
J. Neurol. Neurosurg. Psychiatry,
April 1, 2007;
78(4):
375 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kappos, A. Traboulsee, C. Constantinescu, J. -P. Eralinna, F. Forrestal, P. Jongen, J. Pollard, M. Sandberg-Wollheim, C. Sindic, B. Stubinski, et al.
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Neurology,
September 26, 2006;
67(6):
944 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ge
Multiple Sclerosis: The Role of MR Imaging
AJNR Am. J. Neuroradiol.,
June 1, 2006;
27(6):
1165 - 1176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Dalton, K. A. Miszkiel, P. W. O'Connor, G. T. Plant, G.P.A. Rice, and D. H. Miller
Ventricular enlargement in MS: One-year change at various stages of disease
Neurology,
March 14, 2006;
66(5):
693 - 698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R A Rudick, G R Cutter, M Baier, B Weinstock-Guttman, M K Mass, E Fisher, D M Miller, and A W Sandrock
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
Multiple Sclerosis,
December 1, 2005;
11(6):
626 - 634.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Bermel, S. R. Puli, R. A. Rudick, B. Weinstock-Guttman, E. Fisher, F. E. Munschauer III, and R. Bakshi
Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity
Arch Neurol,
September 1, 2005;
62(9):
1371 - 1376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Pagani, M. A. Rocca, A. Gallo, M. Rovaris, V. Martinelli, G. Comi, and M. Filippi
Regional Brain Atrophy Evolves Differently in Patients with Multiple Sclerosis According to Clinical Phenotype
AJNR Am. J. Neuroradiol.,
February 1, 2005;
26(2):
341 - 346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V L Stevenson, G T Ingle, D H Miller, and A J Thompson
Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study
Multiple Sclerosis,
August 1, 2004;
10(4):
398 - 401.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland
Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients
Neurology,
March 9, 2004;
62(5):
719 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. D. Juengling, J. Kassubek, and Y. Ge
Standardized Calculation of Brain Parenchymal Fraction: An Approach to Objective Assessment of Cerebral Atrophy
AJNR Am. J. Neuroradiol.,
August 1, 2003;
24(7):
1492 - 1493.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E L. Hoogervorst, C H Polman, and F Barkhof
Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone
Multiple Sclerosis,
October 1, 2002;
8(5):
415 - 419.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. F. Kalkers, N. Ameziane, J. C. J. Bot, A. Minneboo, C. H. Polman, and F. Barkhof
Longitudinal Brain Volume Measurement in Multiple Sclerosis: Rate of Brain Atrophy Is Independent of the Disease Subtype
Arch Neurol,
October 1, 2002;
59(10):
1572 - 1576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Rao, N. Richert, T. Howard, B.K. Lewis, C.N. Bash, H.F. McFarland, and J. A. Frank
Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN{beta}-1b
Neurology,
September 10, 2002;
59(5):
688 - 694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Bashir and J. N. Whitaker
Current Immunotherapy for Demyelinating Diseases
Arch Neurol,
May 1, 2002;
59(5):
726 - 731.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Gasperini, A Paolillo, E Giugni, S Galgani, F Bagnato, C Mainero, E Onesti, S Bastianello, and C Pozzilli
MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a
Multiple Sclerosis,
April 1, 2002;
8(2):
119 - 123.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. F. Kalkers, E. Bergers, J. A. Castelijns, M. A. A. van Walderveen, J. C. J. Bot, H. J. Ader, C. H. Polman, and F. Barkhof
Optimizing the association between disability and biological markers in MS
Neurology,
October 9, 2001;
57(7):
1253 - 1258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
